Nominations Open for the Prestigious Tu Youyou Award 2024
5.7.2024 10:00:00 EEST | Business Wire | Press release
MDPI is pleased to announce the opening of nominations for the 2024 Tu Youyou Award, a prestigious recognition established in honor of Professor Tu Youyou, Nobel Laureate, whose discovery has significantly altered the global fight against Malaria.
The Tu Youyou Award offers CHF 100,000
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine for her discovery of artemisinin, significantly reducing mortality rates from malaria and shaping global health policies. Artemisinin-based combination therapies (ACTs) are now the standard treatment endorsed by the World Health Organization (WHO). This groundbreaking work has saved countless lives, especially in regions heavily burdened by Malaria.
To mark Professor Tu's 80th birthday in 2009, MDPI's journal Molecules issued a Special Issue focusing on her contributions to medical research. Recognizing her continuous contribution, MDPI created the Tu Youyou Award in 2016 to honor outstanding achievements in natural products and medicinal chemistry.
The deadline for nominations is 31 December 2024
The Tu Youyou Award offers CHF 100,000, split equally among winners. Nominations are open to scientists excelling in natural products and medicinal chemistry. Eligible nominators include academic institutes, universities, and societies. Nominations close on 31 December 2024, with winners announced on 30 April 2025.
MDPI encourages the academic community to nominate individuals who have demonstrated excellence and innovation akin to Professor Tu’s legacy. This award not only honors individual achievement but also encourages further scientific exploration and discovery in critical areas of medicine.
Stefan Tochev, CEO of MDPI, said, “This award truly embodies our deep commitment to groundbreaking research that drives societal progress and celebrates the legacy of one of the greatest medical innovators of our time.”
For more information, please visit MDPI’s official website or the dedicated Tu Youyou Award page.
About MDPI
MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 diligent, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 445 fully OA titles.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240705939770/en/
Contacts
Rui Duarte, MDPI PR Manager
+41764313242
publicrelations@mdpi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 16:35:00 EET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 16:00:00 EET | Press release
Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contributing. As AI accelerates campaign execution, the quality of each decision matters more.” Intelligence Pro combines four capabilities within Smartly’s platform: Reach Planner helps teams comp
SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 16:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key Highlights Proven platform: medicalforce is used by more than 800 clinics*1 in Japan, primarily self-pay clinics, with a clinic retention rate of 99.2%*2. Joint AI development: Features co-developed by the two companies will enhance medicalforce and be progressively incorpo
NetApp Completes Acquisition of PEAK:AIO to Accelerate Zettabyte-scale AI Deployments2.11.2026 15:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it completed the acquisition of PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. With this acquisition, NetApp can leverage metadata services and parallel namespace innovations to power the fastest storage on the planet, NetApp Novus, to support zettabyte-scale file systems for the most demanding workloads of AI clouds and GPU-as-a-service providers. For the best AI infrastructure economics, organizations need to keep GPU resources continuously supplied with data without bottlenecks. The acquisition advances NetApp’s strategy for the next phase of AI infrastructure by bringing PEAK:AIO’s metadata and parallel file system expertise together with NetApp ONTAP, giving customers a path to AI-scale storage that combines high concurrency and massive namespace growth with the resilience, security, and operational simplicity enterprises already trust
HistoSonics Receives Regulatory Approval in Singapore, Advancing Expansion Across Asia-Pacific2.11.2026 15:00:00 EET | Press release
HistoSonics today announced that the company has received market authorization from Singapore’s Health Sciences Authority (HSA) for its Edison® Histotripsy System (under the device name HistoSonics Histotripsy System), marking another significant milestone in the company’s continued international expansion and creating new opportunities to advance access to histotripsy throughout the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102090757/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image-guided platform that uses the mechanical properties of focused ultrasound, known as histotripsy, to mechanically destroy and liquefy unwanted tissue and tumors. The technology offers a fundamentally new approach to tissue destruction without the need for invasive procedures, radiation, or thermal energy. The Edison System is currently authorized for the destruction of liver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom